ACL australian clinical labs limited

July 20 (Reuters) - Australian Competition and Consumer...

  1. 193,698 Posts.
    lightbulb Created with Sketch. 2825

    July 20 (Reuters) - Australian Competition and Consumer Commission (ACCC):

    • ACL'S PROPOSED ACQUISITION OF HEALIUS RAISES CONCERNS
    • HAS OUTLINED SIGNIFICANT PRELIMINARY COMPETITION CONCERNS WITH AUSTRALIAN CLINICAL LABS LIMITED’S PROPOSED ACQUISITION OF HEALIUS
    • CONCERNED THAT PROPOSED ACQUISITION WOULD BE LIKELY TO SUBSTANTIALLY LESSEN COMPETITION IN AUSTRALIAN PATHOLOGY SERVICES MARKETS
    • PROPOSED ACQUISITION WOULD COMBINE TWO OF TOP THREE PROVIDERS OF PATHOLOGY SERVICES, INCREASING CONCENTRATION IN ALREADY CONCENTRATED MARKETS
    • ACCC INVITES SUBMISSIONS IN RESPONSE TO THE STATEMENT OF ISSUES BY 10 AUGUST 2023
    • PRELIMINARY VIEW IS COMBINED ACL AND HEALIUS MAY BE ABLE TO INCREASE PRICES OR REDUCE SERVICE QUALITY IN BIDS FOR PUBLIC HOSPITAL TENDERS

    (([email protected];))

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$2.83
Change
-0.005(0.18%)
Mkt cap ! $551.8M
Open High Low Value Volume
$2.83 $2.83 $2.78 $1.498M 535.3K

Buyers (Bids)

No. Vol. Price($)
20 8610 $2.82
 

Sellers (Offers)

Price($) Vol. No.
$2.83 6685 16
View Market Depth
Last trade - 15.52pm 29/07/2025 (20 minute delay) ?
ACL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.